denosumab (Rx)

Brand and Other Names:Prolia, Xgeva
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

solution for injection

  • Prolia: 60mg/mL (1mL prefilled syringe or 1mL vial)
  • Xgeva: 70mg/mL (120mg/1.7mL vial)
more...

Osteoporosis

Treatment of men and postmenopausal women with osteoporosis who are at high risk for fracture; treatment to increase bone mass in men at high risk for fracture who are receiving androgen deprivation therapy for nonmetastatic prostate cancer; treatment to increase bone mass in women at high risk for fracture who are receiving adjuvant aromatase inhibitor therapy for breast cancer

Prolia: 60 mg SC every 6 months

Supplement with calcium 1000 mg/day and vitamin D 400 IU/day

Aromatase Inhibitor Induced Bone Loss

Women with breast cancer: 60 mg (Prolia) SC every 6 months

Androgen Deprivation Induced Bone Loss

Men with prostate cancer: 60 mg (Prolia) SC every 6 months

Skeletal-Related Events

Prevention of skeletal-related events (SREs; eg, bone fractures and pain) in patients with multiple myeloma and in patients with bone metastases from solid tumors

Xgeva: 120 mg (1.7 mL) SC every 4 weeks

Giant Cell Tumor

Treatment of adults and skeletally mature adolescents with giant cell tumor of bone in whom surgical resection is impossible or is likely to result in severe morbidity

Xgeva: 120 mg SC every 4 weeks with additional 120 mg on days 8 and 15 during first month of therapy

Hypercalcemia of Malignancy

Indicated for treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy

Xgeva: 120 mg SC q4wk

Give 2 additional 120 mg doses during the first month of therapy on Days 8 and 15

Dosage Forms & Strengths

solution for injection

  • Xgeva: 70mg/mL (120mg/1.7mL vial)
more...

Giant Cell Tumor

Treatment of skeletally mature adolescents with giant cell tumor of bone in whom surgical resection is impossible or is likely to result in severe morbidity

Xgeva: 120 mg SC every 4 weeks, with additional 120 mg on days 8 and 15 during first month of therapy

Next:

Interactions

Interaction Checker

and denosumab

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 
            Previous
            Next:

            Adverse Effects

            >10%

            Back pain (34.7%)

            Extremity pain (11.7%)

            1-10%

            Musculoskeletal pain (7.6%)

            Hypercholesterolemia (7.2%)

            Cystitis (5.9%)

            Upper respiratory tract infection (4.9%)

            New malignancies (4.8%, compared with 4.3% in placebo group)

            Sciatica (4.6%)

            Nonfatal serious infection (4%)

            Bone pain (3.7%)

            Anemia (3.3%)

            Upper abdominal pain (3.3%)

            Rash (2.5%)

            Flatulence (2.2%)

            Osteonecrosis of jaw (2.2%)

            Pruritus (2.2%)

            Hypocalcemia (1.7%)

            <1%

            Serious infection of abdomen resulting in hospitalization (0.9%)

            Serious infection of urinary tract resulting in hospitalization (0.7%)

            Serious infection resulting in death (0.2%)

            Pancreatitis (0.2%)

            Serious infection of ear resulting in hospitalization (0.1%)

            Postmarketing Reports

            Hypocalcemia

            Hypophosphatemia

            Marked elevation in PTH in patients with severe renal impairment or receiving dialysis

            Multiple vertebral fractures following discontinuation of Prolia

            Previous
            Next:

            Warnings

            Contraindications

            History of systemic hypersensitivity, including anaphylaxis, facial swelling, and urticaria

            Preexisting hypocalcemia

            Cautions

            Denosumab is available as 2 distinct brands (Prolia and Xgeva) that have different dosage strengths for their respective indications; do not use concurrently

            Hypocalcemia may occur; monitor calcium levels during therapy, especially in the first weeks of initiating therapy, and adequately supplement all patients with calcium and vitamin D

            Severe symptomatic hypocalcemia has been reported; hypocalcemia may worsen, especially in patients who have CrCl <30 mL/min or are on hemodialysis

            Serious infections (including cellulitis) and dermatologic reactions (eg, dermatitis, rashes, eczema) have been reported; advise patients to seek prompt medical attention if they develop signs or symptoms of infection, including cellulitis; consider discontinuing therapy if severe symptoms develop

            Hypersensitivity (including anaphylaxis) has been reported

            Bone turnover suppression may increase risk for osteonecrosis of jaw; perform an oral examination prior to initiating therapy; osteonecrosis of the jaw, can occur spontaneously and is generally associated with tooth extraction and/or local infection with delayed healing; known risk factors include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders; risk of osteonecrosis of the jaw may increase with duration of therapy

            Significant suppression demonstrated; monitor for consequences of bone oversuppression

            Severe and occasionally incapacitating bone, joint, and/or muscle pain has been reported; discontinue use if severe symptoms develop

            Monitor patients for signs and symptoms of hypercalcemia and treat appropriately

            Atypical femoral fracture has been reported; evaluate patients with thigh or groin pain to rule out a femoral fracture

            Following discontinuation of Prolia treatment, fracture risk increases, including risk of multiple vertebral fractures

            Pancreatitis reported in clinical trials

            Pediatric use is not recommended; drug may impair bone growth in children with open growth plates and may inhibit eruption of dentition

            Latex allergy: If sensitive to latex, do not handle gray needle cap on single-use prefilled syringe, which contains dry natural rubber (a derivative of latex)

            Pregnancy; females of reproductive potential should be advised to use highly effective contraception during therapy and for at least 5 months after last dose (Prolia)

            Not indicated for the prevention of skeletal-related events in patients with multiple myeloma

            Use caution in patients with renal impairment <30 mL/min) or patients on dialysis; risk of hypocalcemia increased; dose adjustment not necessary when administered at 60 mg every 6 months; once monthly dosing not evaluated in patients with renal impairment

            Not for intravenous, intradermal, or intramuscular administration

            Previous
            Next:

            Pregnancy & Lactation

            Pregnancy

            Based on findings in animals and its mechanism of action, denosumab can cause fetal harm when administered to a pregnant woman

            In utero exposusre in cynomolgus monkeys dosed monthly with denosumab throughout pregnancy at a dose 50-fold higher than the recommended human dose based on body weight resulted in increased fetal loss, stillbirths, and postnatal mortality, and absent lymph nodes, abnormal bone growth, and decreased neonatal growth

            Present at low concentrations (approximately 2% of serum exposure) in seminal fluid of male subjects receiving therapy; following vaginal intercourse, maximum amount of denosumab delivered to a female partner would result in exposures approximately 11,000 times lower than the prescribed 60 mg subcutaneous dose; male condom use not necessary as it is unlikely that a female partner or fetus would be exposed to pharmacologically relevant concentrations of denosumab via seminal fluid

            Pregnancy testing

            • Verify pregnancy status of females of reproductive potential prior to initiating treatment

            Lactation

            There is no information regarding presence of denosumab in human milk, effects on breastfed infant, or effects on milk production;

            Detected in maternal milk of cynomolgus monkeys up to 1 month after last dose (≤0.5% milk: serum ratio) and maternal mammary gland development was normal, with no impaired lactation; however, pregnant RANKL knockout mice showed altered maturation of maternal mammary gland, leading to impaired lactation

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next:

            Pharmacology

            Mechanism of Action

            Monoclonal antibody that specifically targets RANKL; binds to RANKL and inhibits its binding to RANK receptor, thereby preventing osteoclast formation; this results in decreased bone resorption and increases bone mass in osteoporosis; in solid tumors with bony metastases, RANKL inhibition decreases tumor-induced bone destruction and SREs

            Absorption

            Peak serum time: 10 days

            Peak plasma concentration: 6.75 mcg/mL

            AUC: 316 mcg•day/mL

            Elimination

            Duration: Markers of bone resorption return to baseline within 12 months of discontinuing therapy

            Half-life: 25.4 days (Prolia); 28 days (Xgeva)

            Previous
            Next:

            Administration

            Subcutaneous Preparation

            Visually inspect for particulate matter and discoloration prior to administration; should be a clear, colorless-to-pale yellow solution that may contain trace amounts of translucent to white proteinaceous particles

            Do not use if discolored or cloudy, or if the solution contains many particles or foreign particulate matter

            Prior to administration, remove from the refrigerator bring to room temperature (up to 25°C/77°F) by standing in the original container; generally takes 15-30 minutes; do not warm in any other way

            Subcutaneous Administration

            Must be administered by healthcare professional

            Use a 27-ga needle to withdraw and inject the entire contents of the vial; do not reenter the vial

            Discard vial after single-dose or entry

            Do NOT administer intradermally, IM, or IV

            Administer SC in upper arm, upper thigh, or abdomen

            Administer calcium and vitamin D as needed to treat or prevent hypocalcemia

            Avoid vigorous shaking of vial/syringe

            Storage

            Refrigerate at 2-8°C (36-46°F); do not freeze

            Once removed from refrigerator, preparation must be used within 14 days and not exposed to temperatures above 25°C (77°F)

            Protect from direct light and heat

            Previous
            Next:

            Images

            Previous
            Next:

            Formulary

            FormularyPatient Discounts

            Adding plans allows you to compare formulary status to other drugs in the same class.

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous